|
| Status |
Public on Oct 17, 2021 |
| Title |
THP1_2H_NVP2_rep3 |
| Sample type |
RNA |
| |
|
| Source name |
THP1 cells treated with NVP2 for 2 hours
|
| Organism |
Homo sapiens |
| Characteristics |
disease state: Acute Myeloid Leukemia
cell line: AML cell line THP-1
agent: NVP2
time: 2 hours
|
| Treatment protocol |
Cells were treated with SY-1365 100nM, NVP2 25nM, Flavopiridol 200nM, JQ1 250nM or DMSO vehicle treatment for 2 or 6hrs. Total RNA was extracted at the timepoint with trizol
|
| Growth protocol |
THP1 cells were purchased from ATCC and cultured according to vendor’s instruction at 37°C in 5% CO2 and in a humidified incubator.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Cells were washed twice with cold PBS before dissolved in trizol. Total RNA isolation was performed following mirVana miRNA isolation kit total RNA extraction protocol.
|
| Label |
biotin
|
| Label protocol |
Protocol of Dana Farber Cancer Institute Molecular Biology Core Facilities
|
| |
|
| Hybridization protocol |
Protocol of Dana Farber Cancer Institute Molecular Biology Core Facilities
|
| Scan protocol |
Protocol of Dana Farber Cancer Institute Molecular Biology Core Facilities
|
| Description |
Gene expression data from THP1 cells treated with NVP2 for 2 hours
|
| Data processing |
Data was processed using the Bioconductor package affy using RMA normalization using the command expresso(raw_data, bgcorrect.method=rma, normalize=TRUE, pmcorrect.method=pmonly, summary.method=medianpolish). This was followed by loess normalization to ERCC spike ins.
|
| |
|
| Submission date |
Oct 16, 2018 |
| Last update date |
Oct 17, 2021 |
| Contact name |
Eric Olson |
| Organization name |
Syros Pharmaceuticals
|
| Street address |
480 Arsenal Street
|
| City |
Watertown |
| State/province |
MA |
| ZIP/Postal code |
02472 |
| Country |
USA |
| |
|
| Platform ID |
GPL16043 |
| Series (2) |
| GSE121291 |
SY-1365, a covalent, first in-class CDK7 inhibitor for cancer treatment (microarray mRNA) |
| GSE121431 |
SY-1365, a covalent, first in-class CDK7 inhibitor for cancer treatment |
|
